Nina Niu Sanford/utswmed.org
Jun 8, 2025, 05:54
Nina Niu Sanford Highlighted Role of NCI National Clinical Trials Network in Cancer Research
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“The NCTN, albeit imperfect, serves a critical role in advancing cancer care by:
1. Conducting pragmatic trials pharma/industry would never sponsor
2. Enrolling across a diverse network (>3K sites) representative of a “real world” population
Great editorial Ted Hong and Thomas George.“
Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute (NCI), shared this post on X, adding:
“Don’t forget: many landmark trials at ASCO25 (e.g. ATOMIC, PDIGREE, CHALLENGE) were powered by National Cancer Institute/NCTN
Such studies ask high-impact, public-benefit questions that industry often won’t/can’t answer.”
Title: Not all trials are created equal: the unique role of the NCI National Clinical Trials Network
Journal: Journal of the National Cancer Institute
Authors: Thomas J George, Theodore S Hong
More posts featuring Nina Niu Sanford on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 1, 2025, 10:32
Jul 1, 2025, 09:57
Jul 1, 2025, 09:25